Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Department of Obstetrics and Gynecology, Nanfang Hospital/The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.
Oncogene. 2019 Feb;38(8):1256-1268. doi: 10.1038/s41388-018-0511-x. Epub 2018 Sep 25.
Cancer-secreted exosomal miRNAs are emerging mediators of cancer-stromal cross-talk in the tumor environment. Our previous miRNAs array of cervical squamous cell carcinoma (CSCC) clinical specimens identified upregulation of miR-221-3p. Here, we show that miR-221-3p is closely correlated with peritumoral lymphangiogenesis and lymph node (LN) metastasis in CSCC. More importantly, miR-221-3p is characteristically enriched in and transferred by CSCC-secreted exosomes into human lymphatic endothelial cells (HLECs) to promote HLECs migration and tube formation in vitro, and facilitate lymphangiogenesis and LN metastasis in vivo according to both gain-of-function and loss-of-function experiments. Furthermore, we identify vasohibin-1 (VASH1) as a novel direct target of miR-221-3p through bioinformatic target prediction and luciferase reporter assay. Re-expression and knockdown of VASH1 could respectively rescue and simulate the effects induced by exosomal miR-221-3p. Importantly, the miR-221-3p-VASH1 axis activates the ERK/AKT pathway in HLECs independent of VEGF-C. Finally, circulating exosomal miR-221-3p levels also have biological function in promoting HLECs sprouting in vitro and are closely associated with tumor miR-221-3p expression, lymphatic VASH1 expression, lymphangiogenesis, and LN metastasis in CSCC patients. In conclusion, CSCC-secreted exosomal miR-221-3p transfers into HLECs to promote lymphangiogenesis and lymphatic metastasis via downregulation of VASH1 and may represent a novel diagnostic biomarker and therapeutic target for metastatic CSCC patients in early stages.
肿瘤微环境中,癌细胞分泌的外泌体 miRNA 正在成为肿瘤基质细胞间通讯的新介质。我们之前对宫颈鳞状细胞癌(CSCC)临床标本的 miRNA 芯片分析发现 miR-221-3p 的表达上调。在此,我们发现 miR-221-3p 与 CSCC 肿瘤周围淋巴管生成和淋巴结(LN)转移密切相关。更重要的是,miR-221-3p 特征性地富集于 CSCC 分泌的外泌体中,并转移到人淋巴管内皮细胞(HLEC)中,促进 HLEC 的迁移和体外管形成,根据功能获得和功能丧失实验,促进体内淋巴管生成和 LN 转移。此外,我们通过生物信息学靶标预测和荧光素酶报告基因检测,确定血管生成素抑制因子 1(VASH1)是 miR-221-3p 的一个新的直接靶标。VASH1 的再表达和敲低分别可以挽救和模拟外泌体 miR-221-3p 诱导的作用。重要的是,miR-221-3p-VASH1 轴在 HLEC 中独立于 VEGF-C 激活 ERK/AKT 通路。最后,循环外泌体 miR-221-3p 水平在体外也具有促进 HLEC 出芽的生物学功能,并且与肿瘤 miR-221-3p 表达、CSCC 患者的淋巴管 VASH1 表达、淋巴管生成和 LN 转移密切相关。总之,CSCC 分泌的外泌体 miR-221-3p 通过下调 VASH1 转移到 HLEC 中,促进淋巴管生成和淋巴转移,可能代表早期转移性 CSCC 患者的一种新的诊断生物标志物和治疗靶点。